<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02463175</url>
  </required_header>
  <id_info>
    <org_study_id>H14-03098</org_study_id>
    <nct_id>NCT02463175</nct_id>
  </id_info>
  <brief_title>Effects of Goal-directed Fluid Therapy on Post-operative Outcomes in Children Undergoing Scoliosis Repair</brief_title>
  <acronym>CardioQ-RP</acronym>
  <official_title>A Randomized Controlled Pilot Study to Examine the Effects of Goal-directed Fluid Therapy on Post-operative Outcomes in Children Undergoing Scoliosis Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surgery for scoliosis correction, the abnormal curvature of the spine, is a major procedure
      often undertaken in adolescents. In adult anesthesia, there is a large volume of literature
      debating how to optimize fluids administered during surgery, as both too much fluid and too
      little fluid are associated with worse outcomes. The investigators will compare fluid
      administration based on the measured amount of blood pumped by the heart during each heart
      beat (goal-directed therapy), against standard anesthetic management. The main outcomes are
      a) post-surgical kidney dysfunction, b) prevalence of intraoperative hypotension, c) volumes
      of administered fluids, and d) length of hospitalization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Written informed consent from parent/guardian and assent from the patient will be
           obtained.

        2. Each patient will be randomized into either the control arm or Cardio Q directed fluid
           therapy arm.

        3. The following standard monitors will be placed before induction of anesthesia:
           electrocardiography, non-invasive blood pressure and pulse oximetry. The patient is
           anesthetized in the supine position using a standardized anesthetic technique. All
           attempts will be made to maintain normothermia

        4. Following induction of anesthesia, the following will be placed: invasive arterial
           cannula, large bore intravenous cannula, Bispectral index monitor, temperature probe and
           central venous cannula (if needed).

        5. Cardiac output monitor: Following induction of anesthesia and after placement of
           appropriate lines and monitors, a transoesophageal doppler (TED) probe will be inserted
           through the mouth into the esophagus and positioned correctly. A normal saline infusion
           will be started once the patient is anesthetized at 0.5 ml/kg/hour in the line where the
           drugs will be infused.

             1. Control Group: In this group, fluid administration, using boluses of 5ml/kg of
                plasmalyte at the anesthesiologist's discretion will be used. Anesthesiologists
                will be blinded to the cardio-Q numerics on the monitor. The flow waveform and
                sound will be available to optimize probe position.

             2. Intervention groups: Boluses of 5ml/kg plasmalyte will be given when: either MAP
                drops 20% from baseline or stroke volume drops 15% from baseline. If the patient is
                fluid responsive, a further 5ml/kg of fluid will be given.

             3. Vasopressor use: MAP (and stroke volume) becomes unresponsive to a fluid bolus then
                a bolus of phenylephrine or ephedrine may be given at the anesthesiologist's
                discretion.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulties with protocol compliance in both arms. Will simplify protocol.
  </why_stopped>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postsurgical kidney dysfunction</measure>
    <time_frame>Postop days 1-3</time_frame>
    <description>Serum creatinine; urine output; urine based interleukin 18 (IL-18) and neutrophil gelatinase-associated lipocalin (NGAL) biomarkers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of intra-operative hypotensive episodes</measure>
    <time_frame>During surgery</time_frame>
    <description>Number of MAP decrease below 75% of baseline reading in pre-anesthesia clinic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent case with intra-operative hypotension</measure>
    <time_frame>During surgery</time_frame>
    <description>Time spent hypotensive (MAP decrease below 75% of baseline reading) normalized by MAP measurement duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of intra-operative spinal cord monitoring changes</measure>
    <time_frame>During surgery</time_frame>
    <description>From the neurological monitoring [when available]: motor evoked potentials (MEP) and somatosensory evoked potentials (SSEP)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Scoliosis</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluid management, boluses of 5ml/kg of plasmalyte, will follow a specific goal-directed fluid therapy (GDT) protocol guided by transesophageal doppler measurement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluid management, using boluses of 5ml/kg of plasmalyte, will follow the current standard of care guided by clinical judgment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plasmalyte</intervention_name>
    <description>Boluses of 5ml/kg of plasmalyte</description>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>crystalloid solution for intravenous infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Goal-directed fluid therapy (GDT)</intervention_name>
    <description>Intraoperative goal-directed fluid therapy (GDT)</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing scoliosis repair

          -  ASA physical status classification system (ASA) I-III

        Exclusion Criteria:

          -  Pre-existing chronic kidney disease

          -  Oropharyngeal disease, e.g. pharyngitis

          -  Esophageal disease, e.g. heartburn, esophageal varices or hiatus hernia.

          -  Coagulopathy

          -  Scheduled for two stage procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zoe E Brown, MBChB, FRCA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.part.cfri.ca</url>
    <description>Pediatric Anesthesia Research Team website</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Matthias GÃ¶rges, PhD</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Fluid Therapy;</keyword>
  <keyword>Transesophageal Doppler</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Scoliosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasma-lyte 148</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

